CA3102483A1 - Il-11 antibodies - Google Patents
Il-11 antibodies Download PDFInfo
- Publication number
- CA3102483A1 CA3102483A1 CA3102483A CA3102483A CA3102483A1 CA 3102483 A1 CA3102483 A1 CA 3102483A1 CA 3102483 A CA3102483 A CA 3102483A CA 3102483 A CA3102483 A CA 3102483A CA 3102483 A1 CA3102483 A1 CA 3102483A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid sequence
- seq
- antigen
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1809699.0A GB201809699D0 (en) | 2018-06-13 | 2018-06-13 | IL-11 antibodies |
| GB1809699.0 | 2018-06-13 | ||
| PCT/EP2019/065598 WO2019238882A1 (en) | 2018-06-13 | 2019-06-13 | Il-11 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3102483A1 true CA3102483A1 (en) | 2019-12-19 |
Family
ID=63042160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3102483A Pending CA3102483A1 (en) | 2018-06-13 | 2019-06-13 | Il-11 antibodies |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11084874B2 (https=) |
| EP (1) | EP3807314A1 (https=) |
| JP (2) | JP2021535733A (https=) |
| KR (1) | KR20210031690A (https=) |
| CN (1) | CN113056481A (https=) |
| AU (2) | AU2019286795B2 (https=) |
| BR (1) | BR112020025443A2 (https=) |
| CA (1) | CA3102483A1 (https=) |
| CL (1) | CL2020003223A1 (https=) |
| CO (1) | CO2020015383A2 (https=) |
| CR (1) | CR20210009A (https=) |
| DO (2) | DOP2020000245A (https=) |
| EA (1) | EA202092668A1 (https=) |
| EC (1) | ECSP21000695A (https=) |
| GB (1) | GB201809699D0 (https=) |
| IL (1) | IL279356A (https=) |
| JO (1) | JOP20200309A1 (https=) |
| MA (1) | MA52884A (https=) |
| MX (1) | MX2020013583A (https=) |
| PE (1) | PE20211498A1 (https=) |
| PH (1) | PH12020552232A1 (https=) |
| SA (1) | SA520420801B1 (https=) |
| SG (1) | SG11202011782XA (https=) |
| TW (1) | TW202003560A (https=) |
| WO (1) | WO2019238882A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| AU2017378111A1 (en) | 2016-12-16 | 2019-06-13 | National University Of Singapore | IL-11 antibodies |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201716733D0 (en) * | 2017-10-12 | 2017-11-29 | Nat Univ Singapore | Treatment of SMC mediated disease |
| TWI858005B (zh) * | 2019-01-21 | 2024-10-11 | 新加坡商新加坡保健服務私人有限公司 | 肝毒性之治療 |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| CN114364693A (zh) | 2019-05-03 | 2022-04-15 | 新加坡保健服务私人有限公司 | 代谢性疾病的治疗和预防 |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| CN116601169A (zh) * | 2020-07-20 | 2023-08-15 | 生物综合治疗有限公司 | 针对马尔堡病毒的广泛中和结合分子 |
| WO2022033538A1 (zh) * | 2020-08-13 | 2022-02-17 | 广东东阳光药业有限公司 | Il-11的抗体及其应用 |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
| CN113980129B (zh) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | 一组il-11单克隆抗体及其医药用途 |
| MX2023009946A (es) | 2021-02-26 | 2023-09-04 | Bayer Ag | Inhibidores de il-11 o il-11ra para uso en el tratamiento de sangrado uterino anormal. |
| US20250092126A1 (en) | 2021-07-26 | 2025-03-20 | Boehringer Ingelheim International Gmbh | Treatment and prevention of alcoholic liver disease |
| JP2024532709A (ja) * | 2021-08-12 | 2024-09-10 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Ｉｌ－１１ヒト化抗体及びその用途 |
| KR20240067079A (ko) | 2021-08-30 | 2024-05-16 | 라센 테라퓨틱스 1, 인코포레이티드 | 항-IL-11Rα 항체 |
| US20250082608A1 (en) | 2021-12-16 | 2025-03-13 | Singapore Health Services Pte Ltd. | Treatment and prevention of glomerular disease |
| CN116891528A (zh) | 2022-01-29 | 2023-10-17 | 迈威(上海)生物科技股份有限公司 | 一种抗白介素-11的抗体及其应用 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| CN118307670A (zh) | 2023-01-06 | 2024-07-09 | 广东东阳光药业股份有限公司 | 抗il-11细胞因子人源化抗体 |
| EP4702047A1 (en) | 2023-04-25 | 2026-03-04 | VVB Bio Pte. Ltd. | Anti il-11 antibody |
| CN120518761B (zh) * | 2023-06-05 | 2025-12-26 | 北京东方百泰生物科技股份有限公司 | 一种结合il-11的抗体、其抗原结合片段及应用 |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| WO2025026206A1 (zh) * | 2023-07-28 | 2025-02-06 | 迈威(上海)生物科技股份有限公司 | 抗白介素-11抗体在制备肿瘤治疗药物中的应用 |
| WO2025108343A1 (zh) * | 2023-11-22 | 2025-05-30 | 上海华奥泰生物药业股份有限公司 | 靶向il-11的抗原结合蛋白 |
| WO2025146029A1 (zh) * | 2024-01-02 | 2025-07-10 | 上海华奥泰生物药业股份有限公司 | 靶向il-11和tslp的多特异性分子 |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
| WO2026001793A1 (zh) * | 2024-06-27 | 2026-01-02 | 上海华奥泰生物药业股份有限公司 | 靶向il-11的抗原结合蛋白及其用途 |
| CN119119262B (zh) * | 2024-08-02 | 2025-05-02 | 杭州曼迪生物科技有限公司 | 一种干细胞冻干粉及其在制备药物或者化妆品中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI335336B (https=) * | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| US8518888B2 (en) * | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) * | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| AU2017378111A1 (en) | 2016-12-16 | 2019-06-13 | National University Of Singapore | IL-11 antibodies |
| RU2016151730A (ru) * | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
-
2018
- 2018-06-13 GB GBGB1809699.0A patent/GB201809699D0/en not_active Ceased
-
2019
- 2019-06-13 MA MA052884A patent/MA52884A/fr unknown
- 2019-06-13 JO JOP/2020/0309A patent/JOP20200309A1/ar unknown
- 2019-06-13 US US16/440,840 patent/US11084874B2/en active Active
- 2019-06-13 PE PE2020001992A patent/PE20211498A1/es unknown
- 2019-06-13 JP JP2020568955A patent/JP2021535733A/ja active Pending
- 2019-06-13 CN CN201980054506.1A patent/CN113056481A/zh active Pending
- 2019-06-13 KR KR1020217000825A patent/KR20210031690A/ko not_active Ceased
- 2019-06-13 MX MX2020013583A patent/MX2020013583A/es unknown
- 2019-06-13 EA EA202092668A patent/EA202092668A1/ru unknown
- 2019-06-13 WO PCT/EP2019/065598 patent/WO2019238882A1/en not_active Ceased
- 2019-06-13 CA CA3102483A patent/CA3102483A1/en active Pending
- 2019-06-13 BR BR112020025443-6A patent/BR112020025443A2/pt unknown
- 2019-06-13 CR CR20210009A patent/CR20210009A/es unknown
- 2019-06-13 TW TW108120516A patent/TW202003560A/zh unknown
- 2019-06-13 SG SG11202011782XA patent/SG11202011782XA/en unknown
- 2019-06-13 AU AU2019286795A patent/AU2019286795B2/en active Active
- 2019-06-13 EP EP19734285.0A patent/EP3807314A1/en active Pending
-
2020
- 2020-12-09 CO CONC2020/0015383A patent/CO2020015383A2/es unknown
- 2020-12-10 IL IL279356A patent/IL279356A/en unknown
- 2020-12-11 CL CL2020003223A patent/CL2020003223A1/es unknown
- 2020-12-11 DO DO2020000245A patent/DOP2020000245A/es unknown
- 2020-12-13 PH PH12020552232A patent/PH12020552232A1/en unknown
- 2020-12-13 SA SA520420801A patent/SA520420801B1/ar unknown
-
2021
- 2021-01-06 EC ECSENADI2021695A patent/ECSP21000695A/es unknown
- 2021-03-25 US US17/212,456 patent/US20210230266A1/en active Pending
-
2024
- 2024-03-01 US US18/592,665 patent/US20240190953A1/en active Pending
- 2024-03-01 US US18/592,746 patent/US20240270837A1/en active Pending
- 2024-05-09 JP JP2024076402A patent/JP2024105466A/ja active Pending
- 2024-10-29 DO DO2024000220A patent/DOP2024000220A/es unknown
-
2026
- 2026-03-05 AU AU2026201704A patent/AU2026201704A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240190953A1 (en) | Il-11 antibodies | |
| US11084878B2 (en) | IL-11Rα antibodies | |
| US11078268B2 (en) | IL-11 antibodies | |
| US20250019461A1 (en) | Her3 antigen-binding molecules | |
| US11078269B2 (en) | IL-11Rα antibodies | |
| WO2024008960A1 (en) | Cnx antigen-binding molecules | |
| EA048010B1 (ru) | Антитела к ил-11 | |
| HK40026637A (en) | Her3 antigen-binding molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240611 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260119 |